The effect of Intravenous immunoglobulin on COVID-19 infectio

Phase 2

Recruiting

• Conditions: COVID-19 disease.; COVID-19; U07.1

• Registration Number: IRCT20200418047116N1
• Lead Sponsor: Gonabad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Positive PCR for COVID -19
Informed consent for inclusion
Hypoxemia not responsive to oxygen therapy
Loss of consciousness (GCS<=14)
Hemodynamic instability
Hypercapnia
Extent of pulmonary involvement
Non-use estrogen-containing compounds
Non-be pregnant or breastfeeding

Exclusion Criteria

Sensitivity to IVIG
IgA deficiency history
Allergic reaction during IVIG injection

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pulmonary manifestations. Timepoint: before and after treatment. Method of measurement: Computed Tomography scan.